

REF. DOCTOR : DR. ARCOFEMI HEALTHCARE LTD **PATIENT NAME : KAVITA** CODE/NAME & ADDRESS : C000138364 ACCESSION NO : 0321WK000773 AGE/SEX :35 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : KAVIF190788246 DRAWN ÷ F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 22/11/2023 08:18:36 DELHI ABHA NO REPORTED :13/12/2023 14:58:18 : NEW DELHI 110030 8800465156 Results **Biological Reference Interval** Units

Test Report Status <u>Final</u> MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE **XRAY-CHEST** IMPRESSION NO ABNORMALITY DETECTED ECG NORMAL SINUS RHYTHM ECG MEDICAL HISTORY RELEVANT PRESENT HISTORY NOT SIGNIFICANT RELEVANT PAST HISTORY P/H/O 1 C - SECTION IN 2012 NOT SIGNIFICANT RELEVANT PERSONAL HISTORY REGULAR MENSTRUAL HISTORY (FOR FEMALES) LMP (FOR FEMALES) 07/11/2023 OBSTETRIC HISTORY (FOR FEMALES) G1,P1,A0,L1 28/04/2012 LCB (FOR FEMALES) RELEVANT FAMILY HISTORY DIABETES NOT SIGNIFICANT OCCUPATIONAL HISTORY HISTORY OF MEDICATIONS NOT SIGNIFICANT **ANTHROPOMETRIC DATA & BMI** HEIGHT IN METERS 1.47 WEIGHT IN KGS. 68.7 BMI 32 BMI & Weight Status as follows/sqmts Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese **GENERAL EXAMINATION** MENTAL / EMOTIONAL STATE NORMAL NORMAL

PHYSICAL ATTITUDE GENERAL APPEARANCE / NUTRITIONAL OBESE STATUS **BUILT / SKELETAL FRAMEWORK** AVERAGE NORMAL FACIAL APPEARANCE NORMAL SKIN NORMAL UPPER LIMB LOWER LIMB NORMAL

P. V. Equilia

Dr.Priyank Kapadia Physician



View Report



mts

Kgs





PATIENT NAME : KAVITA REF. DOCTOR : DR. ARCOFEMI HEALTHCARE LTD CODE/NAME & ADDRESS : C000138364 ACCESSION NO : 0321WK000773 AGE/SEX :35 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : KAVIF190788246 DRAWN ÷ F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 22/11/2023 08:18:36 DELHI ABHA NO REPORTED :13/12/2023 14:58:18 : NEW DELHI 110030 8800465156 Test Report Status Results **Biological Reference Interval** Units <u>Final</u> NORMAL NECK NOT ENLARGED OR TENDER NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED THYROID GLAND **TEMPERATURE** NORMAL 80/MIN PULSE RESPIRATORY RATE NORMAL CARDIOVASCULAR SYSTEM BP 110/70 MM HG mm/Hg (SITTING) NORMAL PERICARDIUM NORMAL APEX BEAT HEART SOUNDS S1, S2 HEARD NORMALLY ABSENT MURMURS **RESPIRATORY SYSTEM** SIZE AND SHAPE OF CHEST NORMAL SYMMETRICAL MOVEMENTS OF CHEST BREATH SOUNDS INTENSITY NORMAL BREATH SOUNDS QUALITY VESICULAR (NORMAL) ADDED SOUNDS ABSENT PER ABDOMEN NORMAL **APPEARANCE** NOT PALPABLE LIVER NOT PALPABLE SPLEEN **CENTRAL NERVOUS SYSTEM** NORMAL HIGHER FUNCTIONS CRANIAL NERVES NORMAL CEREBELLAR FUNCTIONS NORMAL SENSORY SYSTEM NORMAL MOTOR SYSTEM NORMAL NORMAL REFLEXES MUSCULOSKELETAL SYSTEM NORMAL SPINE JOINTS NORMAL

P.V. Equidia

Dr.Priyank Kapadia Physician Page 2 Of 24

View Report







PATIENT NAME : KAVITA REF. DOCTOR : DR. ARCOFEMI HEALTHCARE LTD CODE/NAME & ADDRESS : C000138364 ACCESSION NO : 0321WK000773 AGE/SEX :35 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : KAVIF190788246 : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 22/11/2023 08:18:36 DELHI REPORTED :13/12/2023 14:58:18 ABHA NO : NEW DELHI 110030 8800465156

Test Report Status Final

Results

Biological Reference Interval Units

BASIC EYE EXAMINATION

DISTANT VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT
DISTANT VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT
NEAR VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT
NEAR VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT
COLOUR VISION	NORMAL
SUMMARY	
RELEVANT HISTORY	NOT SIGNIFICANT
RELEVANT GP EXAMINATION FINDINGS	NOT SIGNIFICANT
RELEVANT LAB INVESTIGATIONS	HEMOGLOBIN:- LOW
	ESR:- HIGH
	TRIGLYCERIDES:- HIGH, VLDL:- HIGH
	TSH:- HIGH
RELEVANT NON PATHOLOGY DIAGNOSTICS	USG ABDOMEN:- MILD FATTY LIVER
REMARKS / RECOMMENDATIONS	1) HEMOGLOBIN:- LOW
	ADV:- TAKE MORE DIETARY IRON
	2) ESR:- HIGH
	ADV:- PHYSICIAN OPINION
	3) TRIGLYCERIDES:- HIGH, VLDL:- HIGH
	ADV:- LOW FAT DIET, REGULAR PHYSICAL EXERCISE
	4) TSH:- HIGH
	ADV:- ENDOCRINOLOGIST OPINION

P. V. Kepudia

Dr.Priyank Kapadia Physician Page 3 Of 24

View Report







PATIENT NAME : KAVITA	REF. DOCTOR :	R. ARCOFEMI HEALTHCARE LTD
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : 0321WK000773 PATIENT ID : KAVIF190788246 CLIENT PATIENT ID : ABHA NO :	AGE/SEX :35 Years Female DRAWN : RECEIVED :22/11/2023 08:18:36 REPORTED :13/12/2023 14:58:18
Test Report Status Final	Results Biological	Reference Interval Units

Comments

OUR PANEL DOCTORS FOR NON-PATHOLOGY TESTS:-

CHECK UP DONE BY:- DR. NAMRATA AGRAWAL (M.B.B.S)

REPORT REVIEWED BY:- DR. PRIYANK KAPADIYA (M.B.B.S DNB MEDICINE)

RADIOLOGIST:- DR. SAHIL N SHAH (M.D.RADIOLOGY)

P. V. Kipudia

Dr.Priyank Kapadia Physician

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 4 Of 24





View Report





PATIENT NAME : KAVITA REF. DOCTOR : DR. ARCOFEMI HEALTHCARE LTD CODE/NAME & ADDRESS : C000138364 ACCESSION NO : 0321WK000773 AGE/SEX :35 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : KAVIF190788246 ÷ F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 22/11/2023 08:18:36 DELHI REPORTED :13/12/2023 14:58:18 ABHA NO : NEW DELHI 110030 8800465156 Test Report Status Results Units <u>Final</u>

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

MILD FATTY LIVER

TMT OR ECHO

CLINICAL PROFILE

TMT:- NORMAL

Interpretation(s) MEDICAL

P. V. Kipudia

Dr.Priyank Kapadia Physician

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 5 Of 24





View Report



Test Report Status

<u>Final</u>



Biological Reference Interval Units

PATIENT NAME : KAVITA	REF. DOCTOR :	DR. ARCOFEMI HEALTHCARE LTD
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000773	AGE/SEX : 35 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : KAVIF190788246	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 22/11/2023 08:18:36
NEW DELHI 110030	ABHA NO :	REPORTED :13/12/2023 14:58:18
8800465156		

Results

HAEMATOLOGY - CBC				
MEDI WHEEL FULL BODY HEALTH CHECKUP BEL	OW 40FEMALE			
BLOOD COUNTS, EDTA WHOLE BLOOD				
HEMOGLOBIN (HB) METHOD : PHOTOMETRIC MEASUREMENT	10.8 Low	12.0 - 15.0	g/dL	
RED BLOOD CELL (RBC) COUNT METHOD : COULTER PRINCIPLE	4.02	3.8 - 4.8	mil/µL	
WHITE BLOOD CELL (WBC) COUNT METHOD : COULTER PRINCIPLE	6.02	4.0 - 10.0	thou/µL	
PLATELET COUNT METHOD : COULTER PRINCIPLE	182	150 - 410	thou/µL	
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV) METHOD : CALCULATED	33.2 Low	36.0 - 46.0	%	
MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	82.5 Low	83.0 - 101.0	fL	
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED	26.8 Low	27.0 - 32.0	pg	
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED	32.4	31.5 - 34.5	g/dL	
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	15.4 High	11.6 - 14.0	%	
MENTZER INDEX METHOD : CALCULATED PARAMETER	20.5			
MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM	11.7 High	6.8 - 10.9	fL	
WBC DIFFERENTIAL COUNT				
NEUTROPHILS METHOD : OPTICAL IMPEDENCE & MICROCSOPY	49	40 - 80	%	
LYMPHOCYTES METHOD : OPTICAL IMPEDENCE & MICROCSOPY	38	20 - 40	%	
MONOCYTES METHOD : OPTICAL IMPEDENCE & MICROCSOPY	10	2.0 - 10.0	%	
EOSINOPHILS	3	1.0 - 6.0	%	

Dr.Miral Gajera Consultant Pathologist

Page 6 Of 24

View Report







PATIENT NAME : KAVITA		REF. DOCTOR : DR. A	ARCOFEMI HEALTHCARE LTD
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 032 PATIENT ID : KAV CLIENT PATIENT ID: ABHA NO :	F190788246 DR RE	E/SEX :35 Years Female AWN : CEIVED :22/11/2023 08:18:36 PORTED :13/12/2023 14:58:18
Test Report Status <u>Final</u>	Results	Biological Re	ference Interval Units
METHOD : OPTICAL IMPEDENCE & MICROCSOPY			
BASOPHILS METHOD : IMPEDANCE	0	0 - 1	%
ABSOLUTE NEUTROPHIL COUNT METHOD : CALCULATED	2.95	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT METHOD : CALCULATED PARAMETER	2.29	1.0 - 3.0	thou/µL
ABSOLUTE MONOCYTE COUNT METHOD : CALCULATED PARAMETER	0.60	0.2 - 1.0	thou/µL
ABSOLUTE EOSINOPHIL COUNT METHOD : CALCULATED	0.18	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT METHOD : CALCULATED	0.00 Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR) METHOD : CALCULATED PARAMETER	1.3		
MORPHOLOGY			
RBC METHOD : MICROSCOPIC EXAMINATION	NORMOCYTIC NORM	OCHROMIC	
WBC METHOD : MICROSCOPIC EXAMINATION	Normal Morpholo	DGY	
PLATELETS METHOD : MICROSCOPIC EXAMINATION	ADEQUATE		
REMARKS	NO PREMATURE CEL	LS ARE SEEN. MALARIA	AL PARASITE NOT DETECTED.

METHOD : MICROSCOPIC EXAMINATION

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID-19 patients with mild disease mild become severe. By contrast, when age < 49.5 years old and NLR = 3.46.1% COVID

3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr.Miral Gajera Consultant Pathologist

Page 7 Of 24





View Details

Patient Ref. No. 775000005513200

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KAVITA	REF. DOCTOR : D	R. ARCOFEMI HEALTHCARE LTD
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST		AGE/SEX : 35 Years Female DRAWN : RECEIVED : 22/11/2023 08:18:36
NEW DELHI 110030 8800465156	ABHA NO :	REPORTED :13/12/2023 14:58:18

Test Report Status	s <u>Final</u>
--------------------	----------------

Results

Biological Reference Interval Units

	HAEMATOLOGY		
MEDI WHEEL FULL BODY HEALTH CHECKUP	BELOW 40FEMALE		
ERYTHROCYTE SEDIMENTATION RATE (ESR) BLOOD),EDTA		
E.S.R	35 High	0 - 20	mm at 1 hr
METHOD : WESTERGREN METHOD			
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDT BLOOD	A WHOLE		
HBA1C	4.8	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
METHOD : HPLC			
ESTIMATED AVERAGE GLUCOSE(EAG)	91.1	< 116.0	mg/dL

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-**TEST DESCRIPTION** :-Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. **Decreased** in: Polycythermia vera, Sickle cell anemia

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

LIMITATIONS

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Diagnosing diabetes.
 Identifying patients at increased risk for diabetes (prediabetes).

Dr.Miral Gajera Consultant Pathologist



View Report

Page 8 Of 24

Details



PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KAVITA	REF. DOCTOR : DR. ARCOFEMI HEALTHCARE LTD		
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI		AGE/SEX :35 Years Female DRAWN : RECEIVED :22/11/2023 08:18:36 REPORTED :13/12/2023 14:58:18	
Test Report Status Final	Results Biological	Reference Interval Units	

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range. 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels. 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

 Z.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
 Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results. 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HDF > 25% on alternate pattform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in

Page 9 Of 24









PATIENT NAME : KAVITA REF. DOCTOR : DR. ARCOFEMI HEALTHCARE LTD CODE/NAME & ADDRESS : C000138364 ACCESSION NO : 0321WK000773 AGE/SEX :35 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : KAVIF190788246 DRAWN ÷ F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 22/11/2023 08:18:36 DELHI ABHA NO REPORTED :13/12/2023 14:58:18 : NEW DELHI 110030 8800465156

Test Report Status <u>Final</u> Results

Biological Reference Interval Units

IMMUNOHAEMATOLOGY MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP TYPE AB METHOD : TUBE AGGLUTINATION RH TYPE POSITIVE METHOD : TUBE AGGLUTINATION

Interpretation(s) ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

Dr.Miral Gajera Consultant Pathologist







View Report



PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



Biological Reference Interval Units

PATIENT NAME : KAVITA	REF. DOCTOR : D	R. ARCOFEMI HEALTHCARE LTD
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000773	AGE/SEX : 35 Years Female
	PATIENT ID : KAVIF190788246	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 22/11/2023 08:18:36
NEW DELHI 110030	ABHA NO :	REPORTED :13/12/2023 14:58:18
8800465156		

Test Report Status	<u>Final</u>	Results
<u></u>		BIOCHEMISTRY

DIOCILIPIISTRI				
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE				
GLUCOSE FASTING, FLUORIDE PLASMA				
FBS (FASTING BLOOD SUGAR) METHOD : HEXOKINASE	92	74 - 99	mg/dL	
GLUCOSE, POST-PRANDIAL, PLASMA				
PPBS(POST PRANDIAL BLOOD SUGAR) METHOD : HEXOKINASE	97	70 - 140	mg/dL	
LIPID PROFILE WITH CALCULATED LDL				
CHOLESTEROL, TOTAL	174	Desirable: < 200 BorderlineHigh: 200 - 239 High: > or = 240	mg/dL	
METHOD : ENZYMATIC, COLORIMETRIC			<i>.</i>	
TRIGLYCERIDES	177 High	Desirable: < 150 BorderlineHigh: 150 - 199 High: 200 - 499 Very High: $> $ or $= 500$	mg/dL	
METHOD : ENZYMATIC, COLORIMETRIC				
HDL CHOLESTEROL	46	< 40 Low > or = 60 High	mg/dL	
CHOLESTEROL LDL	93	Adult levels: Optimal < 100 Near optimal/above optimal: 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190	mg/dL	
NON HDL CHOLESTEROL	128	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL	
VERY LOW DENSITY LIPOPROTEIN	35.4 High	< or = 30	mg/dL	
CHOL/HDL RATIO	3.8	3.3 - 4.4		
LDL/HDL RATIO	2.0	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderat Risk >6.0 High Risk		

Dr.Miral Gajera Consultant Pathologist

Page 11 Of 24







/K000773 AGE/SEX : 35 Years Female
90788246 DRAWN : RECEIVED : 22/11/2023 08:18:36
REPORTED :13/12/2023 14:58:18

METHOD : CALCULATED

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk g	roup or recurrent ACS (within 1 year) despite LDL-C < or -	
	50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2 r	najor risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemia	a	
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ		
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary		
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors			
1. Age > or = 45 year	1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use		
2. Family history of p	2. Family history of premature ASCVD 4. High blood pressure		
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	<or 60)<="" =="" td=""><td></td><td></td></or>		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.55	Upto 1.2	mg/dL
BILIRUBIN, DIRECT	0.20	Upto 0.2	mg/dL
METHOD : DIAZO COLORIMETRIC			
BILIRUBIN, INDIRECT	0.35	0.00 - 1.00	mg/dL
TOTAL PROTEIN	7.3	6.4 - 8.3	g/dL
METHOD : COLORIMETRIC			
ALBUMIN	4.6	3.5 - 5.2	g/dL

Dr.Miral Gajera Consultant Pathologist

Page 12 Of 24







PATIENT NAME : KAVITA	R. ARCOFEMI HEALTHCARE LTD		
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321 PATIENT ID : KAVI CLIENT PATIENT ID: ABHA NO :	. WK000773 F190788246	AGE/SEX :35 Years Female DRAWN : RECEIVED :22/11/2023 08:18:36 REPORTED :13/12/2023 14:58:18
Test Report Status <u>Final</u>	Results	Biological	Reference Interval Units
METHOD : BROMOCRESOL GREEN			
GLOBULIN	2.7	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO	1.7	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD : IFCC WITHOUT PYRIDOXAL-5-PHOSPHATE	17	0 - 32	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : IFCC WITHOUT PYRIDOXAL-5-PHOSPHATE	15	0 - 33	U/L
ALKALINE PHOSPHATASE METHOD : COLORIMETRIC	84	35 - 104	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : ENZYMATIC, COLORIMETRIC	15	5 - 36	U/L
LACTATE DEHYDROGENASE METHOD : UV ASSAY METHOD	125 Low	135 - 214	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	7	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE	0.55 Low	0.60 - 1.1	0 mg/dL
METHOD : JAFFE ALKALINE PICRATE			
BUN/CREAT RATIO			
BUN/CREAT RATIO	12.73	5.0 - 15.0	
URIC ACID, SERUM			
URIC ACID	5.0	2.4 - 5.7	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN METHOD : COLORIMETRIC	7.3	6.4 - 8.3	g/dL
ALBUMIN, SERUM			
ALBUMIN METHOD : BROMOCRESOL GREEN	4.6	3.5 - 5.2	g/dL
GLOBULIN			
GLOBULIN	2.7	2.0 - 4.1	g/dL
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM METHOD : ISE	137.9	136 - 145	mmol/L
POTASSIUM, SERUM METHOD : ISE	4.22	3.3 - 5.1	mmol/L

Dr.Miral Gajera Consultant Pathologist

Page 13 Of 24







mmol/L

PATIENT NAME: KAVITA	REF. DOCTOR : DR. ARCOFEMI HEALTHCARE LTD		
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : KAVIF190788246 CLIENT PATIENT ID:	AGE/SEX :35 Years Female DRAWN : RECEIVED :22/11/2023 08:18:36 REPORTED :13/12/2023 14:58:18	

Test Report Status Final

Results

110.2 High

Biological Reference Interval Units

98 - 106

CHLORIDE, SERUM

METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY

Interpretation(s)

Sodium	Potassium	Chioride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Voniting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased In: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium-sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole,	alkalosis. Drugs: chronic laxative,corticosteroids, diuretics. Increased in: Renal failure, nephrotic syndrome, RTA,dehydration, overtreatment with saline,hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis,hyperadrenocorticism. Drugs: acetazolamide,androgens, hydrochlorothiazide,salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s) GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituliarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic with the set of the

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease (onjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin

Dr.Miral Gajera **Consultant Pathologist**

Page 14 Of 24





Details



PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KAVITA	REF. DOCTOR : DR. ARCOFEMI HEALTHCARE LTD		
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI		AGE/SEX :35 Years Female DRAWN : RECEIVED :22/11/2023 08:18:36 REPORTED :13/12/2023 14:58:18	
Test Report Status Final	Results Biological	Reference Interval Units	

may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured consistence of the second of the body. As a second of the body, and is body and the body, heart, second body as a marker for liver health. AST levels increase drinic provide the liver, but also increase drine and the body. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

(hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy,Burns,hemodilution,increased vascular

permeability or decreased lymphatic clearance, malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels:-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Dr.Miral Gaiera Consultant Pathologist



Page 15 Of 24

View Report

/iew Details



PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Guirat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KAVITA	REF. DOCTOR : D	R. ARCOFEMI HEALTHCARE LTD
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000773	AGE/SEX : 35 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : KAVIF190788246	DRAWN :
DELHI	CLIENT PATIENT ID:	RECEIVED : 22/11/2023 08:18:36
NEW DELHI 110030	ABHA NO :	REPORTED :13/12/2023 14:58:18
8800465156		

Test Report	: Status	<u>Final</u>
-------------	----------	--------------

Results

Biological Reference Interval Units

CLINICAL PATH - URINALYSIS				
MEDI WHEEL FULL BODY HEALTH CHECKUP BEL	OW 40FEMALE			
PHYSICAL EXAMINATION, URINE				
COLOR	Yellow			
APPEARANCE	Clear			
CHEMICAL EXAMINATION, URINE				
РН	6.0	4.7 - 7.5		
METHOD : REFLECTANCE SPECTROPHOTOMETRY				
SPECIFIC GRAVITY METHOD : REFLECTANCE SPECTROPHOTOMETRY	<=1.005	1.003 - 1.035		
PROTEIN METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NEGATIVE		
GLUCOSE METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NEGATIVE		
KETONES METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED		
BLOOD METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED		
BILIRUBIN METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED		
UROBILINOGEN METHOD : REFLECTANCE SPECTROPHOTOMETRY	NORMAL	NORMAL		
NITRITE METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED		
LEUKOCYTE ESTERASE METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED		
MICROSCOPIC EXAMINATION, URINE				
RED BLOOD CELLS METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED	/HPF	
PUS CELL (WBC'S) METHOD : MICROSCOPIC EXAMINATION	1-2	0-5	/HPF	
EPITHELIAL CELLS METHOD : MICROSCOPIC EXAMINATION	3-5	0-5	/HPF	
CASTS METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED			

Dr.Miral Gajera Consultant Pathologist

Page 16 Of 24

View Report







PATIENT NAME : KAVITA REF. DOCTOR : DR. ARCOFEMI HEALTHCARE LTD CODE/NAME & ADDRESS : C000138364 ACCESSION NO : 0321WK000773 AGE/SEX :35 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : KAVIF190788246 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 22/11/2023 08:18:36 DELHI REPORTED :13/12/2023 14:58:18 ABHA NO : NEW DELHI 110030 8800465156 **Test Report Status** Results Biological Reference Interval Units <u>Final</u>

CRYSTALS	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION		
BACTERIA	NOT DETECTED	NOT DETECTED
METHOD : MICROSCOPIC EXAMINATION		
YEAST	NOT DETECTED	NOT DETECTED
METHOD : MICROSCOPIC EXAMINATION		
REMARKS	MICROSCOPIC EXAMINATION OF URINE IS CARRIED OUT ON	
	CENTRIFUGED URINARY SEDIMENT.	

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 17 Of 24

Vie<u>w Report</u>







PATIENT NAME : KAVITA	REF. DOCTOR : DR. ARCOFEMI HEALTHCARE LTD		
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : 0321WK000773 PATIENT ID : KAVIF190788246 CLIENT PATIENT ID: ABHA NO :	AGE/SEX : 35 Years Female DRAWN : RECEIVED : 22/11/2023 08:18:36 REPORTED : 13/12/2023 14:58:18	
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units	

Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 18 Of 24

18

View Report







PATIENT NAME : KAVITA	REF. DOCTOR : DR. ARCOFEMI HEALTHCARE LTD		
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	i de la constancia de la c	AGE/SEX :35 Years Female DRAWN : RECEIVED :22/11/2023 08:18:36 REPORTED :13/12/2023 14:58:18	
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units	

Results

	CYTOLOGY
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 40FEMALE
PAPANICOLAOU SMEAR	
TEST METHOD	CONVENTIONAL GYNEC CYTOLOGY
SPECIMEN TYPE	TWO UNSTAINED CERVICAL SMEARS RECEIVED
REPORTING SYSTEM	2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY
SPECIMEN ADEQUACY	SMEARS ARE SATISFACTORY FOR EVALUATION.
MICROSCOPY	SMEARS SHOW PREDOMINANTLY SUPERFICIAL AND INTERMEDIATE SQUAMOUS CELLS AGAINST BACKGROUND OF MILD ACUTE INFLAMMATION. ENDOCERVICAL CELLS NOT SEEN ON SMEAR. NO EVIDENCE OF DYSPLASIA OR MALIGNANT CELLS SEEN.
INTERPRETATION / RESULT	NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

Comments

PAP SMEAR IS A SCREENING PROCEDURE FOR CERVICAL CANCER WITH INHERENT FALSE NEGATIVE RESULTS HENCE RESULTS SHOULD BE INTERPRETED WITH CAUTION.

Dr.Miral Gajera Consultant Pathologist



View Report

View Details



PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel: 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KAVITA	REF. DOCTOR : DR. ARCOFEMI HEALTHCARE LTD		
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0321WK000773 PATIENT ID : KAVIF190788246 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :35 Years Female DRAWN : RECEIVED :22/11/2023 08:18:36 REPORTED :13/12/2023 14:58:18	

Test Report	Status	<u>Final</u>
-------------	--------	--------------

Results

Biological Reference Interval Units

c	LINICAL PATH - STOOL ANALY	YSIS	
MEDI WHEEL FULL BODY HEALTH CHEC	KUP BELOW 40FEMALE		
PHYSICAL EXAMINATION, STOOL			
COLOUR	BROWN		
CONSISTENCY	WELL FORMED		
MUCUS	NOT DETECTED	NOT DETECTED	
VISIBLE BLOOD	ABSENT	ABSENT	
ADULT PARASITE	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION			
CHEMICAL EXAMINATION, STOOL			
STOOL PH	NEGATIVE		
OCCULT BLOOD	NOT DETECTED	NOT DETECTED	
METHOD : HEMOSPOT			
MICROSCOPIC EXAMINATION, STOOL			
PUS CELLS	NOT DETECTED		/hpf
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION			
CYSTS	NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION			
OVA METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED		
	NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED	
TROPHOZOITES	NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION			
FAT	ABSENT		
VEGETABLE CELLS	ABSENT		
CHARCOT LEYDEN CRYSTALS	ABSENT		
Interpretation(s)			

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF

CONDITION

Dr.Miral Gajera Consultant Pathologist

Page 20 Of 24

View Report









PATIENT NAME: KAVITA	REF. DOCTOR : DR. ARCOFEMI HEALTHCARE LTD			
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000773	AGE/SEX	:35 Years	Female
	PATIENT ID : KAVIF190788246	DRAWN	:	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED	:22/11/2023	08:18:36
NEW DELHI 110030	ABHA NO :	REPORTED	:13/12/2023	14:58:18
8800465156				
	I i i i i i i i i i i i i i i i i i i i	I		

Test Report Status Final

Results

Biological Reference Interval Units

Pus cells	Pus in the stool is an indication of infection
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days.Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.
Charcot-Leyden crystal	Parasitic diseases.
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.
Frank blood	Bleeding in the rectum or colon.
Occult blood	Occult blood indicates upper GI bleeding.
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.
рН	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.

ADDITIONAL STOOL TESTS :

- <u>Stool Culture</u>:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if treatment for GI infection worked.
- Fecal Calprotectin: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).
- 3. Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.
- <u>Clostridium Difficile Toxin Assay</u>: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to
 overuse of broad spectrum antibiotics which alter the normal GI flora.
- Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array Test, (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- <u>Rota Virus Immunoassay</u>: This test is recommended in severe gastroenteritis in infants & children associated with watery diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

Dr.Miral Gajera Consultant Pathologist

Page 21 Of 24

Vie<u>w Report</u>



View Details

Patient Ref. No. 775000005513200

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KAVITA	REF. DOCTOR : DR. ARCOFEMI HEALTHCARE LTD		
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL		AGE/SEX : 35 Years Female	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI		DRAWN : RECEIVED : 22/11/2023 08:18:36	
	ABHA NO :	REPORTED :13/12/2023 14:58:18	

Test Report Status Final

Results

Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE				
MEDI WHEEL FULL BODY HEALTH CHECKUP B	ELOW 40FEMALE			
THYROID PANEL, SERUM				
T3	113.20	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0	D	
METHOD : ECLIA T4 METHOD : ECLIA	8.76	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70		
TSH (ULTRASENSITIVE)	5.590 High	Non Pregnant Women 0.27 - 4.20 Pregnant Women (As per American Thyroid Associatio 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000)	

METHOD : ECLIA

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No. TSH Total T4 FT4 Total T3	Possible Conditions
-----------------------------------	---------------------

Dr.Miral Gajera Consultant Pathologist



Page 22 Of 24

Vie<u>w Report</u>

View Details

Patient Ref. No. 775000005513200

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KAVITA	REF. DOCTOR : DR. ARCOFEMI HEALTHCARE LTD			
	ACCESSION NO : 0321WK000773	AGE/SEX : 35 Years Female		
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID :KAVIF190788246	DRAWN :		
DELHI	CLIENT PATIENT ID:	RECEIVED : 22/11/2023 08:18:36		
NEW DELHI II0030	ABHA NO :	REPORTED :13/12/2023 14:58:18		
8800465156				

Test Report Status <u>Final</u>

Results

Biological Reference Interval Units

1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)	
					Post Thyroidectomy (4) Post Radio-Iodine treatment	
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid	
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto	
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical	
					inflammation, drugs like amphetamines, lodine containing drug and	
					dopamine antagonist e.g. domperidone and other physiological reasons.	
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism	
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre	
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid	
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4	
					replacement therapy (7) First trimester of Pregnancy	
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism	
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor	
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent	
					treatment for Hyperthyroidism	
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness	
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies	

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association duriing pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> **End Of Report** Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in









PATIENT NAME : KAVITA	REF. DOCTOR : DR. ARCOFEMI HEALTHCARE LTD			
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : 0321WK000773 PATIENT ID : KAVIF190788246 CLIENT PATIENT ID: ABHA NO :	AGE/SEX : 35 Years Female DRAWN : RECEIVED : 22/11/2023 08:18:36 REPORTED : 13/12/2023 14:58:18		
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units		

CONDITIONS OF LABORATORY TESTING & REPORTING

 It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
 All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.

3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

4. A requested test might not be performed if:

- i. Specimen received is insufficient or inappropriate
- ii. Specimen quality is unsatisfactory
- iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

8. Test results cannot be used for Medico legal purposes.

9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

(JIII) JIII) within 40 hours of the report

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 24 Of 24





